KD Ventures: riktad emission om MSEK 7.6
Modus Therapeutics, som är ett portföljbolag till KDventures, har genomfört en riktad nyemission om MSEK 7.6. Emissionen ska finansiera bolagets utvecklingsplan för läkemedelskandidaten sevuparin under 2027. KDventures ägarandel i Modus Therapeutics efter transaktionen uppgår till 51 procent, vilket gör att kapitaltillskottet kan påverka portföljbolagets fortsatta utvecklingsarbete.
- Riktad nyemission om MSEK 7.6 med 20,000,000 aktier till ett pris om SEK 0.38 per aktie.
- Emissionslikviden ska användas för att finansiera utveckling av sevuparin under 2027 samt tillverkning och aktiviteter kopplade till bland annat forskningssamarbete inom svår malaria.
- KDventures ägarandel i Modus Therapeutics efter transaktionen uppgår till 51 procent.
- Kursreaktion
- +15,7 %
- Sedan publicering
- RVOL vid samma tid
- Saknas
- 21 sep.
- RVOL mot heldag
- 0,1×
- 21 sep. · 20 dagars snitt
Aktiekurs
Mätpunkter & underlag
Aktien 21 sep.
- Senaste kurs
- 0,269 SEK
21 sep. 17:30
- Föregående stängning
- 0,279 SEK
2026-09-18
- Handlad volym
- 156 668 aktier
21 sep. 17:29
- Jämförelseunderlag
- 0 handelsdagar · preliminärt
21 sep. mot föregående stängning
−3,4 %RVOL vid samma tid jämför den kumulativa volymen med samma klockslag tidigare handelsdagar. RVOL mot heldag jämför med snittet för 20 hela handelsdagar. Det är bolagets handel, inte volym orsakad av nyheten.
Handelsdagen ovan är senare än nyhetens första börssession.
Leverantörens stängningskurs; justering för bolagshändelser är inte verifierad.
Läs hela källtexten
STOCKHOLM, SWEDEN September 4, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company Modus Therapeutics has carried out a directed issue of MSEK 7.6. The net proceeds will finance the company’s development plan for the drug candidate sevuparin during 2027.
STOCKHOLM, SWEDEN September 4, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company Modus Therapeutics has carried out a directed issue of MSEK 7.6. The net proceeds will finance the company’s development plan for the drug candidate sevuparin during 2027. Investors in the directed issue are Tellus Equity AB, Selandia Alpha Invest A/S, and certain existing minor shareholders. The directed issue of 20,000,000 shares was subscribed at a price of SEK 0.38 per share, resulting in net proceeds of MSEK 7.6 before transaction costs. The net proceeds will be used to manufacture pharmaceutical product for future activities, for example, in the research cooperation within severe malaria, as well as business development activities in case the ongoing phase 2a study in chronic kidney disease with anemia generates positive data. “Modus Therapeutics is approaching a critical value-driving inflection point, with proof-of-concept data expected around the turn of the year. The rights issue is a well-considered and necessary step to enable the company to act decisively on the opportunities that may arise, both in its drug development work and in business development. We also welcome new larger shareholders who share our view of the company’s potential and long-term value creation,” says Viktor Drvota, CEO of KDventures. KDventures' ownership in Modus Therapeutics after the transaction amounts to 51 percent. Contacts Viktor Drvota, CEO, KDventures AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@kd-ventures.com Johan Dighed, General Counsel and Deputy CEO, KDventures AB Phone: +46 70 207 48 26, e-mail: johan.dighed@kd-ventures.com About Us KDventures AB (Nasdaq Stockholm: KDV) is a Nordic investment company specialized in life sciences. The company identifies and invests in innovative pharmaceutical projects and medical technology products originating from leading research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, KDventures creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with significant value growth potential. For more information, please visit https://www.kd-ventures.com/en. Attachments KDventures portfolio company Modus Therapeutics carries out a directed issue of MSEK 7.6 (https://storage.mfn.se/6451d748-1911-4c97-9f25-3af442f38282/kdventures-portfolio-company-modus-therapeutics-carries-out-a-directed-issue-of-msek-7-6.pdf)
Källor & underlag